Digoxin Injection
Product Images NDC 51662-1217

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Digoxin (NDC 51662-1217). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

00351662121726 Digoxin Pouch Label

This is a medication in the form of an ampule, with a concentration of 250mcg/mL and a volume of 2mL. The medication is for slow intravenous or deep intramuscular use and does not require dilution. The usual dosage instructions can be found in the package insert. The medication must be stored at a temperature between 20°C and 25°C (68°F and 77°F). The manufacturer is HF Acquisition Co., LLC and the original NDC is 0641-1410-35.*

FDA Label Image

00351662121733 Digoxin Rfid Label

FDA Label Image

00351662121733 Digoxin Case Label

Digoxin Injection is a medication used for slow intravenous or deep intramuscular use with a concentration of 500mcg/2mL (250mcg/mL), which comes in a box of 25 2 mL amps. Dilution is not required, and dosage should be determined by a professional based on the full prescribing information in the package insert. The lot number is L2asss, and the expiration date is 2025-01-01. The medication should be stored at controlled room temperature (20°C-25°C/68°F-77°F), and to open the ampoules, they should be broken at construction. The manufacturer is HF Acquisition Co., LLC, located in Mukilteo, WA 98275. RX only.*

FDA Label Image

Ampule (1000180 0641 1410 31 Digoxin Ampule Label)

FDA Label Image

Serialized Label (51662 1217 1 Digoxin Serialized)

FDA Label Image

Clinical (Clinical Pharmacology Tabel)

This text provides information about the Time to Onset of Effect and Time to Peak Effect for Digoxin tablets and injection/IV. Digoxin tablets have a Time to Onset of Effect of 0.5-2 hours and a Time to Peak Effect of 2-6 hours, whereas Digoxin Injection/IV has a Time to Onset of Effect of 5-30 minutes and a Time to Peak Effect of 1-4 hours.*

FDA Label Image

Dosage 1 (Dosage And Admin Tabel 1)

This text does not provide enough information to generate a useful description. It appears to be incomplete and lacks context.*

FDA Label Image

Dosage 2 (Dosage And Admin Tabel 2)

This text provides limited information and is not clear on what it's describing. It appears to be stating the number of patients who are adults and pediatric, and their age range. Without additional context, it is not possible to provide a useful description.*

FDA Label Image

Dosage 3 (Dosage And Admin Tabel 3)

This appears to be a table showing the relationship between lean body weight, creatinine, and the number of days it takes to achieve steady clearance state in patients. The table provides values for different levels of creatinine (in kg) and corresponding steady clearance states achieved in different number of days. The values in the table vary based on the mL/min level, ranging from 10 mL/min to 100 mL/min.*

FDA Label Image

Dosage 4 (Dosage And Admin Tabel 4)

This appears to be a chart or table displaying the absolute equivalent doses (measured in micrograms or mcg) and bioavailability for two forms of the medication digoxin: tablets and intravenous injection. The bioavailability percentage is listed as 60-80% for the tablets and 100% for the injection. The chart displays the dosages available for the tablets (62.5, 125, 250, 500 mcg) and the injection (50, 100, 200, 400 mcg). This table could be useful for healthcare professionals who prescribe or administer digoxin to patients.*

FDA Label Image

Interactions 1 (Drug Interaction Tabel 1)

Digoxin concentrations can increase by more than 50% when taken with Quinidine or Ritonavir. It is recommended to measure serum digoxin levels before initiating concomitant drugs and reduce the dose by approximately 30-50%. Amiodarone and Propafenone can cause an increase in digoxin concentration by up to 29%, while Quinine and Spironolactone increase it by up to 38% and 24%, respectively. Verapamil can also increase digoxin concentration by up to 24%.*

FDA Label Image

Interactions 2 (Drug Interactions Tabel 2)

This text provides a list of drugs and treatments that can affect renal function and potentially interact with digoxin, a medication commonly used to treat heart failure and certain arrhythmias. The text highlights the risk of cardiac arrhythmias and sudden death when taking digoxin in combination with certain drugs, such as antiarrhythmics, sympathomimetics, neuromuscular blocking agents, and supplements like calcium. It is important for healthcare professionals to consider potential drug interactions and closely monitor patients receiving digoxin.*

FDA Label Image

Logo (Logo Patient Cons)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.